Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health concern. The development of vaccines with high immunogenicity and safety is crucial for controlling the global COVID-19 pandemic and preventing furth...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology Vol. 12; p. 766112
Main Authors:	Tran, Thi Nhu Mai, May, Bruce Pearson, Ung, Trong Thuan, Nguyen, Mai Khoi, Nguyen, Thi Thuy Trang, Dinh, Van Long, Doan, Chinh Chung, Tran, The Vinh, Khong, Hiep, Nguyen, Thi Thanh Truc, Hua, Hoang Quoc Huy, Nguyen, Viet Anh, Ha, Tan Phat, Phan, Dang Luu, Nguyen, Truong An, Bui, Thi Ngoc, Tu, Tieu My, Nguyen, Thi Theo, Le, Thi Thuy Hang, Dong, Thi Lan, Huynh, Trong Hieu, Ho, Phien Huong, Le, Nguyen Thanh Thao, Truong, Cong Thao, Pham, Hoang Phi, Luong, Cong Y, Y, Nie Lim, Cao, Minh Ngoc, Nguyen, Duy Khanh, Le, Thi Thanh, Vuong, Duc Cuong, Nguyen, Le Khanh Hang, Do, Minh Si
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 06-12-2021
Subjects:	ACE2 Animals Antibodies, Neutralizing - immunology Antibodies, Viral - immunology CHO COVID-19 COVID-19 - prevention & control COVID-19 Vaccines - immunology COVID-19 Vaccines - toxicity Cricetinae Immunogenicity, Vaccine - immunology Immunology Macaca Mice Rats RBD SARS-CoV-2 Spike Glycoprotein, Coronavirus - immunology Vaccines, Synthetic - immunology Vaccines, Synthetic - toxicity COVID-19 ACE2 SARS-CoV-2 CHO RBD
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health concern. The development of vaccines with high immunogenicity and safety is crucial for controlling the global COVID-19 pandemic and preventing further illness and fatalities. Here, we report the development of a SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the spike (S) protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG and neutralizing antibodies in three animal models: BALB/c mouse, Syrian hamster, and a non-human primate ( ). In addition, a viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. Nanocovax did not induce any adverse effects in mice ( var. albino) and rats ( ). These preclinical results indicate that Nanocovax is safe and effective.
Bibliography:	Reviewed by: Marc Paul Girard, Université Paris Diderot, France; Srinivasa Reddy Bonam, Institut National de la Santé et de la Recherche Médicale (INSERM), France Edited by: Michael Vajdy, EpitoGenesis, United States These authors share first authorship This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
ISSN:	1664-3224 1664-3224
DOI:	10.3389/fimmu.2021.766112